Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of [18F]Florbetazine in Healthy Subjects and Patients with AD/MCI
NCT06593626Phase 1Completed
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Florbetapir in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms). Primary endpoint: Adverse events (AE) and their incidence at 30 days. Started Nov 2023; status: completed.
02
Drugs
Florbetapir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06593626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593626.